NEWS ANALYSIS | Oct 9, 2026 | Kratom Truth Project
On October 9, the Department of Justice announced updated emergency scheduling actions targeting 7-hydroxymitragynine and related kratom alkaloids. The Notice of Intent was published in the Federal Register on October 14. The temporary scheduling order cannot take effect before November 13, 2026. The DEA may publish it on or after that date with no further notice required. There is no announced publication date.
This is the third major scheduling action in a four-month campaign. Here is the complete timeline, what changed, and what it means.
The Full Timeline
June 1, 2026: The National Institutes of Health — an agency within the Department of Health and Human Services — filed an Investigational New Drug application to develop a prescription mitragynine-derived drug for opioid use disorder treatment. The compound is derived from the primary alkaloid in natural kratom leaf.
July 1, 2026: The Drug Enforcement Administration — an agency within the Department of Justice — transmitted two Notices of Intent to temporarily schedule 7-hydroxymitragynine above a specified threshold and related synthetic compounds. Published in the Federal Register on July 6. The agency invoked 21 U.S.C. § 811(h), the emergency scheduling authority that allows placement in Schedule I to address "an imminent hazard to the public safety" without completing standard notice-and-comment rulemaking.
July 31, 2026: The public comment window on the 7-OH threshold closed with 32,149 comments submitted.
August 5, 2026: The earliest date the DEA could have issued the temporary scheduling order for 7-OH. That date passed without action.
August 26, 2026: DEA published the temporary scheduling order for mitragynine pseudoindoxyl, MGM-15, and MGM-16, effective immediately through August 26, 2028. On the same day, DEA extended the 7-OH comment period through September 10.
September 10, 2026: The extended public comment period for 7-OH closed. The comment period is now permanently closed.
October 8, 2026: HHS sent a new letter to DEA revising its recommendation. Rather than scheduling 7-OH alone above its original threshold of 0.05%, HHS now recommends scheduling 7-hydroxymitragynine and mitragynine pseudoindoxyl together when their combined concentration exceeds a new specified threshold of 1mg per gram. The FDA cited "new scientific information" as the basis for this change. That scientific information has not been made public.
October 9, 2026: DOJ announced DEA is issuing new Notices of Intent based on the October 8 HHS letter. The same day, the American Kratom Association announced it was withdrawing its lawsuit against the DEA. Mac Haddow, AKA Senior Fellow on Public Policy, stated: "We made an agreement to dismiss our lawsuit, but it's conditioned on their publishing under the schedule that they submitted to the court. The thresholds draw the line the AKA has been asking for, targeting chemically concentrated products."
October 14, 2026: The revised Notices of Intent were published in the Federal Register as document 2026-20943.
November 13, 2026 or later: The earliest date the temporary scheduling order for 7-OH can take effect. August 5 was also an earliest date — the DEA let it pass by more than three months. November 13 is a floor, not a deadline. The order can publish on any business day on or after that date. It takes effect the day it publishes. There will be no additional public notice.
What Changed in October
The original July proposal targeted 7-OH alone above a threshold of 0.05% by dry weight. The October revision creates a combined threshold approach: 7-hydroxymitragynine and mitragynine pseudoindoxyl together, either substance alone or their combined amount if both are present, above 1mg per gram.
Two things changed. The threshold for 7-OH alone is actually less restrictive than the July proposal — 1mg per gram is 0.1%, double the July threshold of 0.05%. But the combined approach reaches further by targeting total alkaloid concentration across both compounds rather than each separately. A product containing each below the individual threshold could still be captured if the combined amount exceeds 1mg per gram.
The AKA's acceptance of this framework is significant. Their lawsuit challenged the original scheduling approach. Their withdrawal of that lawsuit upon the announcement of the new thresholds signals that the kratom industry's own trade organization views the new threshold as a workable line that protects botanical kratom while targeting concentrated products. Whether that confidence is warranted will depend on how the order is enforced and what comes next in the permanent scheduling process.
What the Comment Period Was and Was Not
Thirty-two thousand people submitted comments. The comment period is now closed. There will be no further opportunity for public input before the order takes effect.
This is how temporary scheduling under § 811(h) works. The comment period that existed was for HHS's threshold recommendation, not for the DEA's actual scheduling order. Temporary scheduling orders are issued directly by the DEA Administrator under emergency authority. Per the Federal Register notice: "since DEA believes this temporary scheduling action is not a 'rule,' it is not subject to the requirements of the RFA when issuing this temporary action."
Temporary scheduling orders are not subject to judicial review.
The only legal pathway to challenge a scheduling action is through the permanent scheduling process — a separate, multi-year rulemaking with a formal eight-factor analysis, a comment period, and judicial review. That process has not been initiated.
The Imminent Hazard Standard — Still Not Documented
The entire legal basis for emergency temporary scheduling under § 811(h) is that scheduling is "necessary to avoid an imminent hazard to the public safety."
The DEA has invoked this standard three times now in this action — in July, in August for MP and MGM compounds, and now in October. The evidence supporting the imminent hazard finding has not been made public in the way that permanent scheduling evidence would be. No eight-factor analysis, no formal scientific review record, no documented body count from 7-OH alone at natural leaf concentrations.
The CDC's own peer-reviewed data shows 91% of kratom-detected deaths explicitly involved at least one other substance. The remaining 9% are not confirmed kratom-caused deaths — they are cases where another cause could not be definitively established. There are zero confirmed single-substance deaths from natural kratom in the federal record. The scholarly literature contains no documented case of death caused by 7-OH at naturally occurring concentrations in kratom leaf.
"Imminent hazard to public safety" is a legal standard, not a scientific one. The DEA has the authority to invoke it. What it has not done is publish the primary evidence that would satisfy that standard under scientific scrutiny — because the temporary scheduling mechanism does not require it to.
The Timing That Requires Explanation
On June 1, 2026, the NIH — part of HHS — filed to develop a prescription mitragynine-derived drug for opioid use disorder.
Thirty days later, the DEA moved to schedule 7-OH and related kratom alkaloids.
Both NIH and the FDA are within HHS. The same department funding development of a prescription kratom-derived pharmaceutical also recommended scheduling naturally occurring kratom alkaloids that compete with that pharmaceutical.
Memorial Sloan Kettering Cancer Center and Columbia University hold active patents on mitragynine analogs. Sparian Biosciences and Kures/ATAI Life Sciences are in clinical development of prescription kratom-derived OUD treatments. Those products become commercially viable at the moment natural kratom alkaloids become legally unavailable in concentrated form.
Whether this represents coordinated commercial strategy or independent regulatory judgment is a question the primary sources raise and do not answer. What the primary sources establish is the timeline, the institutional relationships, and the financial stakes.
What Is Not Being Scheduled
Natural kratom leaf. Ground kratom powder. Kratom products containing 7-OH and mitragynine pseudoindoxyl below the 1mg per gram combined threshold.
FDA Commissioner Makary has stated explicitly that the agency is not targeting the kratom leaf or ground kratom. The threshold approach is designed to reach concentrated extracts and synthetic derivatives while leaving botanical kratom below the line. The AKA's acceptance of the framework reflects their assessment that the line is drawn in the right place.
The immediate practical concern for consumers is vendor compliance. The long-term concern is the permanent scheduling process — what standards will govern it, what evidence will be required, and whether the threshold framework holds or becomes a platform for further restriction.
What Happens Next
The temporary order cannot take effect before November 13. It could take effect any business day after that with no additional notice. Once it takes effect it remains in effect for two years, extendable by one year if permanent scheduling proceedings are pending.
Permanent scheduling — the process that would involve a full eight-factor analysis, public comment, and judicial review — has not been initiated. It would be a separate proceeding that could run concurrently with the temporary order.
32,149 people submitted comments. The comment period is closed. The next formal opportunity for public input would be the permanent scheduling process, if and when it is initiated.
Federal Register Notice: FR-2026-20943, published October 14, 2026. Docket DEA-1570. DOJ press release dated October 9, 2026. Primary documents at federalregister.gov and justice.gov.
The NIH IND filing and the patent race context: kratomtruthproject.org/the-patent-race-synthetic-kratom-the-cannabis-playbook
The 7-OH science and scheduling analysis: kratomtruthproject.org/7-oh-science-fraud
